| 8.83 -0.2 (-2.21%) | 08-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.65 |
1-year : | 13.61 |
| Resists | First : | 9.97 |
Second : | 11.65 |
| Pivot price | 1.69 |
|||
| Supports | First : | 4.39 |
Second : | 0.94 |
| MAs | MA(5) : | 2.8 |
MA(20) : | 1.52 |
| MA(100) : | 1.52 |
MA(250) : | 1.58 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 60.2 |
| RSI | RSI(14): 95.3 |
|||
| 52-week | High : | 9.97 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MBAI ] has closed above the upper band by 43.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1381.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10 - 10.04 | 10.04 - 10.09 |
| Low: | 8.23 - 8.28 | 8.28 - 8.32 |
| Close: | 8.75 - 8.83 | 8.83 - 8.9 |
Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.
Thu, 13 Aug 2026
Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective - The Manila Times
Tue, 11 Aug 2026
Check-Cap to implement 1-for-7 reverse stock split Wednesday - Investing.com UK
Fri, 07 Aug 2026
Check-Cap (NASDAQ: MBAI) sets 1-for-7 reverse split and share consolidation - Stock Titan
Fri, 07 Aug 2026
Check-Cap Announces Reverse Share Split - The Manila Times
Fri, 24 Jul 2026
Check-Cap Ltd. (NASDAQ: MBAI) plans MBody AI merger and new share offering - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 37.4 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 78 (K) |
| Shares Short P.Month | 127 (K) |
| EPS | 0.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | 416.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 13.37 |
| PEG Ratio | 0 |
| Price to Book value | 18.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -1483.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|